Etizolam

From Wikipedia, the free encyclopedia

Etizolam
Systematic (IUPAC) name
?
Identifiers
CAS number 40054-69-1
ATC code N05BA19
PubChem 3307
DrugBank ?
Chemical data
Formula C17H15ClN4S 
Mol. mass 342.8
Pharmacokinetic data
Bioavailability 93%
Metabolism Hepatic
Half life about 6 hours
Excretion Renal
Therapeutic considerations
Pregnancy cat.

?

Legal status

Schedule IV(US)

Routes Oral

Etizolam (marketed under the brand name Sedekopan or Depas) is a drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties.

Etizolam is not approved for sale in the United States or Canada.


Contents

[edit] Indications

[edit] Dosage

  • For anxiety: 0,25-0,50 mg two or three times per day (maximum 2 mg per day)
  • For insomnia: 1 or 2 mg before bedtime

[edit] Pharmacology

According to the Italian P.I. sheet (please correct my poor English please):

Etizolam belongs to a new class of diazepines, thienotriazolodiazepines. This new class is easily oxidized, rapidly metabolized, and has a lower risk of accumulation, even after prolonged treatment. Etizolam has an anxiolytic action about 6 times greater than that of diazepam. Etizolam produces, especially at higher dosages, a reduction in time taken to fall asleep, an increase in total sleep time and a reduction in the number of awakenings. During tests there were not substantial changes in deep sleep. There is a reduction of REM sleep, but REM rebound at the end of treatment was not seen. In EEG tests of healthy volunteers Etizolam showed some characteristics of tricyclic antidepressants. Etizolam is free of significant effects on the cardiovascular and respiratory systems.

In men, peak time is at 3.2 hours, and half-life is about 6.2 hours. So it can be classified as a short-medium action bendodiazepine.

[edit] External links


Languages